Prostate Cancer Clinical Trial
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve radiation therapy planning and patient selection for dRT, and potentially improve its outcome compared to dRT without PSMA PET (standard dRT).
I. To compare the outcome of patients with unfavorable intermediate (IR) and high-risk (HR) prostate cancer (PCa) after standard dRT versus prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-based dRT.
OUTLINE: Patients are randomized to 1 of 2 arms. In both arms, no other primary treatment should be given before RT.
Arm I: Patients do not undergo PSMA PET for dRT planning. Patients undergo standard of care dRT at the discretion of the treating radiation oncologist.
Arm II: Patients undergo PSMA PET for dRT planning. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives the PSMA PET result and images.
After completion of dRT, clinical follow-up of patients with their treating radiation oncologist will be obtained for 5 years. The investigators will rely on the medical records obtained from the treating physicians as the primary source of outcome data.
Adult male 18 years or older
Unfavorable IR to HR disease:
Prostate specific antigen (PSA) >= 10 ng/mL
Or cT-stage >= 2b
Or Gleason grade 3 (4+3=7) or higher
Or Gleason grade 2 (3+4=7) AND >= 50% positive biopsy cores
Or Decipher Score >= 0.45
Treating radiation oncologist intends to incorporate PSMA PET findings into the radiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Less than 18 years old at the time of investigational product administration
Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done before randomization
Prior PSMA PET
Prior pelvic RT
Contraindications to radiotherapy (including active inflammatory bowel disease)
Concurrent or prior surgery or systemic therapy for PCa at the time of randomization
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, 90095, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.